Healthy Adult
Conditions
Keywords
Bioequivalence, Healthy Subjects, Donepezil
Brief summary
The purpose of this study is to investigate the bioequivalence of improved and current orally disintegrating E2020 10 mg tablets as a single dose in Japanese healthy adult males for each of two administration methods (with/without water).
Interventions
DRUGDonepezil Hydrochloride
improved orally disintegrating E2020 10 mg tablet without water.
Sponsors
Eisai Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 44 Years
Healthy volunteers
Yes
Inclusion criteria
Those who meet all below criteria are eligible to enroll in this study; 1. Those who provide consent by their own will. 2. Male subjects aged between ≥ 20 years and \< 45 years old at the time of obtaining informed consent and non-smoker (subjects who have not been smoking for at least 4 weeks prior to study treatment) 3. BMI at screening is 18.5 kg/m2 or above and less than 25.0 kg/m2 4. Those who are willing to and can comply with the conditions described in the study protocol.
Exclusion criteria
Those who meet any of the below criteria will be excluded from the study. 1. Any significant medical illness that required intervention within 8 weeks before treatment, or any medical history of clinically significant infectious diseases within 4 weeks before treatment. 2. Those who had any psychiatric, GI tract, hepatic, renal, respiratory, endocrine, hematological, neurological, cardiovascular diseases or congenital metabolic disorders within 4 weeks before study drug administration that may have an impact on the evaluation of the drug. 3. Subjects who have any medical history of GI, hepatic, or renal surgery (e.g. excision of liver, kidney or GI tract) that may have an impact on pharmacokinetics of the drug. 4. Subjects who have any history of medically significant allergy to medications or foods, and those who currently have any symptoms of seasonal 5. Subjects whose weight changes were more than 10% from the screening phase to study drug administration. 6. Those with clinical abnormal symptoms, medical history of organ dysfunction, subjective symptoms, objective findings, vital signs, and abnormal EKG or clinical laboratory test values, which need medical intervention. 7. Corrected change in QT wave (QTc) interval of \> 450 msec with 12-lead EKG at screening or study drug administration. 8. Subjects who are positive for hepatitis B surface antigen (HBs antigen), hepatitis C (HCV) antibody, or serologic test for syphilis (STS). 9. Subjects who are suspected with or who has a history of drug or alcohol abuse, or positive urine screen for drugs of abuse or exhalation alcohol test at screening or baseline. 10. Subjects who consumed caffeine-containing food or beverages within 72 hours before study drug administration. 11. Exposure to any supplements or herbs (including Chinese medicine), or beverages (e.g. alcohol or grapefruit-containing beverages, within 2 weeks of study drug administration. 12. Exposure to St. John's wort containing medications within 4 weeks of study drug administration. 13. Use of any prescription drugs within 4 week before study drug administration. 14. Use of any OTC medications within 2 week before study drug administration. 15. Subjects who enrolled in another clinical trial and exposed to any investigational drug within 16 weeks of study enrollment. 16. Subjects who received blood infusion within 12 weeks, those who had blood drawn 400 mL or more within 12 weeks, 400 mL, or 200 mL or more within 4 weeks, or sampling of a component of the blood within 2 week of study drug administration. 17. Subjects who performed extreme exercises or exhausting labors (more than 1 hr/day or 5 day/week) within 2 weeks before hospitalization. 18. Any subject who, or whose partner, does not want to take highly reliable contraceptive measures until the end of the post-treatment examination. 19. Subjects who are inappropriate to participate in the study, as judged by the investigator or subinvestigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PK Parameter Cmax, calculated from plasma E2020 concentration by a non-compartmental analysis, will be evaluated. | Up to 168 hrs after administration |
| PK Parameter AUC(0-168), calculated from plasma E2020 concentration by a non-compartmental analysis, will be evaluated. | Up to 168 hrs after administration |
Countries
Japan
Outcome results
None listed